Description

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology, such as PD-L1, as well as novel targets, comprising CD-166. In addition, it has strategic collaborations with Bristol-Myers Squibb Company, Pfizer Inc., ImmunoGen, Inc., and The University of Texas M. D. Anderson Cancer Center to develop selected Probody therapeutics. The company was founded in 2008 and is headquartered in South San Francisco, California.